For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
21
views
32
references
 Top references
cited by
56
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      141
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

          Noopur Raje, Jesus Berdeja, Yi Lin … (2019)
          Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
          Article 0 comments Cited 632 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A note on quantifying follow-up in studies of failure time.

            Michael Schemper, Terry L Smith (1996)
            Article 0 comments Cited 448 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

              Sagar Lonial, Hans C Lee, Ashraf Z Badros … (2019)
              Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study.
              Article 0 comments Cited 292 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): J Clin Oncol
                Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
                Publisher: American Society of Clinical Oncology (ASCO)
                ISSN (Electronic): 1527-7755
                ISSN (Print): 0732-183X
                Publication date (Electronic): Mar 01 2021
                Volume: 39
                Issue: 7
                Affiliations
                [1 ] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
                [2 ] Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain.
                [3 ] Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
                [4 ] Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
                [5 ] Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
                [6 ] Clínica Universidad de Navarra, Pamplona, Spain.
                [7 ] CHU de Poitiers, Poitiers, France.
                [8 ] Division of Hematology-Oncology, Department of Medicine, University of Florida, Gainesville, FL.
                [9 ] Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
                [10 ] Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France.
                [11 ] Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), Nantes, France.
                [12 ] Service d'hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis Ricordeau, Nantes, France.
                [13 ] Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain.
                [14 ] Rush University Medical Center, Chicago, IL.
                [15 ] Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX.
                [16 ] The Oncology Institute of Hope and Innovation, Glendale, CA.
                [17 ] Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
                [18 ] Novant Health Hematology, Novant Health Forsyth Medical Center, Winston-Salem, NC.
                [19 ] Oncopeptides AB, Stockholm, Sweden.
                [20 ] Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.
                Article
                DOI: 10.1200/JCO.20.02259
                PMC ID: 8078327
                PubMed ID: 33296242
                SO-VID: 35f89e28-49ac-4113-befb-3539158eca4a
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content141

                See all similar

                Cited by56

                See all cited by

                Most referenced authors775

                See all reference authors